Low-grade systemic inflammation profile, unrelated to homocysteinemia, in obese children

Mediators of Inflammation

Volumn 2005, Issue 6, 2005, Pages 337-342

  Economou, Emanuel V ^a   Malamitsi Puchner, Ariadne V ^a   Pitsavos, Christos P ^b   Kouskouni, Evangelia E ^a   Magaziotou Elefsinioti, Ioanna ^c   Creatsas, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; HOMOCYSTEINE;

ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC LOW GRADE SYSTEMIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HOMOCYSTINURIA; HUMAN; INFLAMMATION; LEAN BODY WEIGHT; MALE; OBESITY; PREPUBERTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHOOL CHILD;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHILD; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INFLAMMATION; MALE; OBESITY; RISK FACTORS; SERUM AMYLOID A PROTEIN;

EID: 29144530193     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI.2005.337     Document Type: Article

References (30)

1. Kiess W, Galler A, Reich A, et al. Clinical aspects of obesity in childhood and adolescence. Obes Rev. 2001;2(1):29-36.
2. Desideri G, De Simone M, Iughetti L, et al. Early activation of vascular endothelial cells and platelets in obese children. J Clin Endocrinol Metab. 2005;90(6):3145-3152.
3. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17(11-12):953-966.
4. Ford ES, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH. C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Pediatr. 2001;138(4):486-492.
5. Matsubara T, Ishibashi T, Hori T, et al. Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. Mol Cell Biochem. 2003;249(1-2):67-73.
6. Svatikova A, Wolk R, Shamsuzzaman AS, Kara T, Olson EJ, Somers VK. Serum amyloid A in obstructive sleep apnea. Circulation. 2003;108(12):1451-1454.
7. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest. 1996;26(6):427-435.
8. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem. 1998;44(6 pt1):1358-1361.
9. Wilkins J, Gallimore JR, Tennent GA, et al. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem. 1994;40(7 pt 1):1284-1290.
10. Valle M, Martos R, Gascon F, Canete R, Zafra MA, Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab. 2005;31(1):55-62.
11. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation. 1997;96(9):2914-2919.
12. Retterstol L, Eikvar L, Berg K. A twin study of C-reactive protein compared to other risk factors for coronary heart disease. Atherosclerosis. 2003;169(2):279-282.
13. Danesh J,Whincup P,Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321(7255):199-204.
14. Economou E, Pitsavos C, Stefanadis C, et al. Serum amyloid A levels in patients with mild to moderate hypertension, before and after treatment with a calcium antagonist. Im: American College of Cardiology 48th Annual Scientific Session; March, 1999; New Orleans, La. Abstract 1223-1272.
15. Kisilevsky R, Tam SP. Acute phase serum amyloid A, cholesterol metabolism, and cardiovascular disease. Pediatr Pathol Mol Med. 2002;21(3):291-305.
16. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290(7):932-40.
17. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol. 1998;18(12):1895-1901.
18. Gallistl S, Sudi KM, Erwa W, Aigner R, Borkenstein M. Determinants of homocysteine during weight reduction in obese children and adolescents. Metabolism. 2001;50(10):1220-1223.
19. Gallistl S, Sudi K, Mangge H, Erwa W, Borkenstein M. Insulin is an independent correlate of plasma homocysteine levels in obese children and adolescents. Diabetes Care. 2000;23(19):1348-1352.
20. Economou EV, Malamitsi-Puchner AV, Pitsavos CP, et al. Negative association between circulating total homocysteine and proinflammatory chemokines MCP-1 and RANTES in prepubertal lean, but not in obese, children. J Cardiovasc Pharmacol. 2004;44(3):310-315.
21. Galli-Tsinopoulou A, Karamouzis M, Nousia-Arvanitakis S. Insulin resistance and hyperinsulinemia in prepubertal obese children. J Pediatr Endocrinol Metab. 2003;16(4):555-560.
22. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol. 2001;21(6):968-970.
23. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism. 2003;52(9):1113-1116.
24. Pirro M, Siepi D, Lupattelli G, et al. Plasma C-reactive protein in subjects with hypo/hyperalphalipoproteinemias. Metabolism. 2003;52(4):432-436.
25. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003;166(2):387-394.
26. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis. 2001;156(2):451-456.
27. McDermott MM, Greenland P, Green D, et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation. 2003;107(25):3191-3198.
28. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148(2):209-214.
29. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J. 1999;20(13):954-959.
30. Gomez-Ambrosi J, Salvador J, Paramo JA, et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem. 2002;35(4):315-320.